Gastric Cancer Clinical Trial
Official title:
A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
NCT number | NCT04149691 |
Other study ID # | 01FGFR2018 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 1 |
First received | |
Last updated | |
Start date | July 19, 2019 |
Est. completion date | June 2024 |
The purpose of the study is to determine to evaluate safety and tolerability of CPL304110 when administered once daily to adults with advanced solid malignancies.
Status | Recruiting |
Enrollment | 42 |
Est. completion date | June 2024 |
Est. primary completion date | June 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years and older |
Eligibility | Inclusion Criteria: - Patient or legal guardian, if permitted by local regulatory authorities, provides informed consent to participate in the study must be performed before any procedure's protocol related - age of =25 years old - Performance Score =70 in accordance with the Karnofsky Performance Score (KPS), - life expectancy period of at least 3 months on the screening day, - Have measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - subject (or his/her partner) of childbearing potential willingness to use acceptable forms of contraception - adequate blood, liver, renal and urine parameters - phosphate levels within normal range - HIV, HCV (hepatitis C virus) and HBV negative (hepatitis B virus), - adequate cardiac function Inclusion Criteria Specific for parts: Part 1 - Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, cholangiocarcinoma, sarcoma or endometrial cancer, be refractory to prior therapies and without effective further treatment options. Part 2 and 3 - Patients with histologically confirmed advanced gastric cancer, bladder cancer, squamous lung cancer or non-small cell lung cancer with squamous immunophenotype, be refractory to prior therapies and without effective further treatment options. - Subject's archival formalin-fixed paraffin-embedded (FFPE) tumour sample available for molecular alteration diagnostics, and/or a possibility to collect a new biopsy. - Present molecular alteration within FGFR 1, 2 or 3 Exclusion Criteria: - Any other current malignancy or malignancy diagnosed within the past five (5) years. - Active brain metastases or leptomeningeal metastases. - concurrent anticancer treatment within 28 days before the start of trial treatment; major surgery within 28 days before the start of trial treatment); use of blood transfusion within 7 days before the start of trial treatment, - prior therapy with an agent directed to another FGFR inhibitor, - pregnancy and/or breastfeeding, - phosphate levels above the upper limit of normal, - ectopic calcification/mineralization, - endocrine alteration related to calcium/phosphate homeostasis e.g. parathyroid disorders, history of parathyroidectomy, - concomitant therapies increasing calcium/phosphate serum levels, - inability to take oral medicines, - corneal disorder and/or keratopathy, - persisting toxicity related to prior therapy Grade > 1 CTCAE v5.0, except polyneuropathy and alopecia, - clinically significant (i.e., active) cardiovascular disease. History of abdominal fistula, bowel obstruction (Grade IV), gastrointestinal perforation, intra-abdominal abscess within 6 months of enrollment. Other significant diseases, which, in the opinion of the investigator, might impair the subject's tolerance of trial treatment. - Receipt of any organ transplantation including allogeneic stem-cell transplantation. Exclusion Criteria Specific for parts: Part 2 and 3 - No FFPE tumour sample available to conduct FGFR alteration eligibility tests and no biopsy option. |
Country | Name | City | State |
---|---|---|---|
Poland | Uniwersyteckie Centrum Kliniczne w Gdansku | Gdansk | |
Poland | BioResearch Group sp. z o.o. | Nadarzyn | |
Poland | SP ZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie | Olsztyn | |
Poland | Klinika Onkologii, Europejskie Centrum Zdrowia | Otwock | |
Poland | Centrum Onkologii - Instytut im. Marii Sklodowskiej-Curie | Warsaw | |
Poland | Instytut Gruzlicy i Chorób Pluc | Warsaw | |
Poland | Wojskowy Instytut Medyczny | Warsaw |
Lead Sponsor | Collaborator |
---|---|
Celon Pharma SA | National Center for Research and Development, Poland |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum tolerated dose (MTD) | Maximum tolerated dose (MTD) of CPL304110 when administered orally once daily to adults with advanced solid malignancies. The MTD is the highest dose associated with the occurrence of dose-limiting toxicities (DLTs) in <33% of patients. | First cycle of 28 days | |
Primary | Safety profile | Overall safety profile of CPL304110, as assessed by the type, frequency, severity, timing, and relationship to study drug of any adverse events (AEs), serious adverse events (SAEs), and changes in vital signs, ECGs, and safety laboratory test. | First cycle of 28 days | |
Secondary | Recommended Phase 2 Dose (RP2D) determined on the base of the MTD. | The RP2D will be determined after review and discussion of the pharmacokinetics (PK) profile, type and severity of drug related toxicity and clinical suitability for long-term administration. | Approximately up to 12 months | |
Secondary | ORR, objective rate response | ORR, objective rate response defined as the rate of confirmed complete response (CR) or partial response (PR) by RECIST 1.1. | Approximately up to 12 months | |
Secondary | Maximum plasma concentration (Cmax) | Cmax defines the maximum concentration of the product in plasma during observation period. | up to 24 hours after CPL304110 administration | |
Secondary | Time to maximum plasma concentration (tmax) | tmax defines Time to reach maximum plasma concentration | up to 24 hours after CPL304110 administration | |
Secondary | Area under the plasma concentration versus time curve (AUC) from 0 up to the time of last quantifiable concentration (AUC0-t) | AUC(0-t) defines the area under the curve of plasma concentration vs time, from time point zero up to the time of last quantifiable concentration | up to the time of last quantifiable concentration after CPL304110 administration | |
Secondary | Area under the plasma concentration versus time curve AUC from 0 to infinity (AUC0-inf) | AUC0-inf defines the area under the curve of plasma concentration vs time, from time point zero extrapolated to infinity | up to 24 hours after CPL304110 administration | |
Secondary | Terminal half-life (t½) | Plasma elimination half-life | up to 24 hours after CPL304110 administration | |
Secondary | Kel: Terminal elimination rate constant | Terminal elimination rate constant | up to 24 hours after CPL304110 administration |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |